TY - JOUR
T1 - Human Trypanosoma cruzi infection and seropositivity in dogs, Mexico
AU - Estrada-Franco, Jose G.
AU - Bhatia, Vandanajay
AU - Diaz-Albiter, Hector
AU - Ochoa-Garcia, Laucel
AU - Barbabosa, Alberto
AU - Vazquez-Chagoyan, Juan C.
AU - Martinez-Perez, Miguel A.
AU - Guzman-Bracho, Carmen
AU - Garg, Nisha
PY - 2006/4
Y1 - 2006/4
N2 - We used 5 diagnostic tests in a cross-sectional investigation of the prevalence of Trypanosoma cruzi in Tejupilco municipality, State of Mexico, Mexico. Our findings showed a substantial prevalence of immunoglobulin G (IgG) and IgM antibodies to T. cruzi in human (n = 293, IgG 2.05%, IgM 5.5%, both 7.1%) and dog (n = 114, IgG 15.8%, IgM 11.4%, both 21%) populations. We also found antibodies to T. cruzi (n = 80, IgG 10%, IgM 15%, both 17.5%) in dogs from Toluca, an area previously considered free of T. cruzi. Our data demonstrate the need for active epidemiologic surveillance programs in these regions. A direct correlation (r2 = 0.955) of seropositivity between humans and dogs suggests that seroanalysis in dogs may help identify the human prevalence of T. cruzi infection in these areas.
AB - We used 5 diagnostic tests in a cross-sectional investigation of the prevalence of Trypanosoma cruzi in Tejupilco municipality, State of Mexico, Mexico. Our findings showed a substantial prevalence of immunoglobulin G (IgG) and IgM antibodies to T. cruzi in human (n = 293, IgG 2.05%, IgM 5.5%, both 7.1%) and dog (n = 114, IgG 15.8%, IgM 11.4%, both 21%) populations. We also found antibodies to T. cruzi (n = 80, IgG 10%, IgM 15%, both 17.5%) in dogs from Toluca, an area previously considered free of T. cruzi. Our data demonstrate the need for active epidemiologic surveillance programs in these regions. A direct correlation (r2 = 0.955) of seropositivity between humans and dogs suggests that seroanalysis in dogs may help identify the human prevalence of T. cruzi infection in these areas.
UR - http://www.scopus.com/inward/record.url?scp=33645469804&partnerID=8YFLogxK
U2 - 10.3201/eid1204.050450
DO - 10.3201/eid1204.050450
M3 - Artículo
SN - 1080-6040
VL - 12
SP - 624
EP - 630
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 4
ER -